Company Overview
About Alveus Therapeutics
Alveus Therapeutics is applying mRNA medicine to pulmonary diseases by developing inhaled mRNA formulations that deliver protein replacement or gene editing instructions directly to lung cells. Unlike systemic mRNA therapeutics that require IV infusion and liver targeting, Alveus's inhaled approach delivers mRNA locally to lung epithelial cells, enabling treatment of diseases like idiopathic pulmonary fibrosis (IPF), COPD, and cystic fibrosis with potentially lower doses and fewer systemic side effects.
Business Model & Competitive Advantage
The company's lipid nanoparticle formulations for pulmonary delivery draw on lessons from COVID-19 mRNA vaccine manufacturing and Moderna's pulmonary delivery research. Alveus was founded in 2023 by pulmonology and mRNA delivery experts and raised $150M in a 2025 Series A, reflecting investor enthusiasm for respiratory applications of mRNA technology following vaccine success.
Competitive Landscape 2025–2026
IPF affects 100,000+ patients annually in the U.S. with no curative options — current approved therapies only slow progression. Alveus's IND-enabling studies target a 2026 first-in-human milestone for its lead IPF program, with pipeline expansion into RSV and influenza mRNA vaccines that leverage the inhaled delivery platform.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Alveus Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Alveus Therapeutics has achieved $150M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
80 Acres Farms
80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Honda
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded
Compare Alveus Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alveus Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alveus Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alveus Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →